Merck seeks more deals to prepare for Keytruda revenue decline

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-02-04 07:00 GMT | Update On 2024-03-22 08:40 GMT

Merck & Co on Thursday said it was in the market for deals of up to around $15 billion as it plans for a loss of revenue from its aging cancer immunotherapy Keytruda, the world's top-selling prescription medicine.

The drugmaker, which also reported better-than-expected fourth-quarter results on strong Keytruda sales, has already inked multiple deals over the last year, including a $5.5 billion payout to Japan's Daiichi Sankyo for the right to co-develop three antibody drug conjugate cancer drugs.

"While I feel very good about the progress we've made and the growing portfolio, the diverse and deep portfolio we have in our pipeline, we do continue to believe we need more, and we will continue to prioritize business development," Chief Executive Officer Rob Davis said on a conference call.

In addition to deals, Davis said Merck would look for more collaborations similar to the Daiichi Sankyo transactions.

Keytruda generated $25 billion in 2023 sales, surpassing peak sales of AbbVie's blockbuster arthritis drug Humira.

Keytruda is forecast to top $30 billion in sales by 2026. However, the drug is set to lose its patent protection by the end of the decade.

The company's 2023 transactions are already significantly improving Merck's own outlook for future revenue. Merck said it now expects $20 billion from new oncology products in development by the mid-2030s, nearly double its prior oncology pipeline forecast for over $10 billion.

It also lifted its mid-2030s outlook for new cardiometabolic products to about $15 billion from more than $10 billion.

Merck reported adjusted earnings of 3 cents a share in the fourth quarter, despite taking a charge of $1.69 a share to account for the Daiichi deal. Analysts had expected a loss of 11 cents a share, according to LSEG data.

Revenue for the quarter rose 6% to $14.6 billion, compared with estimates of $14.5 billion.

Keytruda sales jumped 21% to $6.6 billion as the company was able to increase use of the drug in earlier stage cancers, topping analyst forecast of $6.5 billion.

The company forecast 2024 sales between $62.7 billion and $64.2 billion. Analysts, on average, are estimating 2024 sales of $63.5 billion.

The New Jersey-based drugmaker expects 2024 earnings of $8.44 to $8.59 per share, above Wall Street estimates of $8.42.

Merck also said it has launched a restructuring program to optimize its manufacturing operations related to human and animal health, and expects to complete the program by the end of 2031.

Merck expects to record about $4 billion in cumulative pre-tax costs to implement the program. It took a $190 million charge related to the program in the fourth quarter.

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/merck-posts-better-than-expected-quarterly-results-soaring-keytruda-sales-2024-02-01/#:~:text=Keytruda%20is%20forecast%20to%20top,own%20outlook%20for%20future%20revenue.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Merck seeks more deals to prepare for Keytruda revenue decline

Similar News

Akum Pharma Asked to Submit Safety Data for Alzheimer's Drug Combo In Elderly Indian Patients

Aurobindo Pharma net profit drops 10 percent to Rs 824 crore in Q1

MSN Labs Gets CDSCO Panel Nod to Begin Phase III Trial of Cenobamate Tablets, With Safety Caveat

USFDA appoints Sean Keveney as Chief Counsel

Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma

Cipla Bommasandra facility gets VAI classification from USFDA

Eli Lilly expands India presence with inauguration of Hyderabad site

Setback To Novartis: CDSCO Panel Rejects Lanalumab Phase III Trial Design Over Study Flaws